384 related articles for article (PubMed ID: 30546360)
21. Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.
Martin TG; Corzo K; Chiron M; Velde HV; Abbadessa G; Campana F; Solanki M; Meng R; Lee H; Wiederschain D; Zhu C; Rak A; Anderson KC
Cells; 2019 Nov; 8(12):. PubMed ID: 31779273
[TBL] [Abstract][Full Text] [Related]
22. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
Krejcik J; Casneuf T; Nijhof IS; Verbist B; Bald J; Plesner T; Syed K; Liu K; van de Donk NW; Weiss BM; Ahmadi T; Lokhorst HM; Mutis T; Sasser AK
Blood; 2016 Jul; 128(3):384-94. PubMed ID: 27222480
[TBL] [Abstract][Full Text] [Related]
23. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.
van de Donk NW; Moreau P; Plesner T; Palumbo A; Gay F; Laubach JP; Malavasi F; Avet-Loiseau H; Mateos MV; Sonneveld P; Lokhorst HM; Richardson PG
Blood; 2016 Feb; 127(6):681-95. PubMed ID: 26631114
[TBL] [Abstract][Full Text] [Related]
24. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
25. CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond.
Roccatello D; Fenoglio R; Sciascia S; Naretto C; Rossi D; Ferro M; Barreca A; Malavasi F; Baldovino S
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32531894
[TBL] [Abstract][Full Text] [Related]
26. α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma.
Teiluf K; Seidl C; Blechert B; Gaertner FC; Gilbertz KP; Fernandez V; Bassermann F; Endell J; Boxhammer R; Leclair S; Vallon M; Aichler M; Feuchtinger A; Bruchertseifer F; Morgenstern A; Essler M
Oncotarget; 2015 Mar; 6(7):4692-703. PubMed ID: 25576914
[TBL] [Abstract][Full Text] [Related]
27. Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials.
Ye W; Wu X; Liu X; Zheng X; Deng J; Gong Y
BMC Cancer; 2021 Sep; 21(1):994. PubMed ID: 34488679
[TBL] [Abstract][Full Text] [Related]
28. Daratumumab in multiple myeloma.
Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
[TBL] [Abstract][Full Text] [Related]
29. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
[No Abstract] [Full Text] [Related]
30. Frontline Therapy for Fit MM Patients Should Include an Antibody.
Voorhees P
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S81-S83. PubMed ID: 32862881
[No Abstract] [Full Text] [Related]
31. Current antibody-based therapies for the treatment of multiple myeloma.
Varga C; Waldschmidt JM; Gandolfi S; Richardson PG
Clin Adv Hematol Oncol; 2020 Nov; 18(11):736-748. PubMed ID: 33406065
[TBL] [Abstract][Full Text] [Related]
32. [CD38 antibodies in multiple myeloma].
Moreaux J
Med Sci (Paris); 2019 Dec; 35(12):1001-1004. PubMed ID: 31903907
[TBL] [Abstract][Full Text] [Related]
33. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
34. Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma.
Bannas P; Koch-Nolte F
Front Immunol; 2018; 9():2559. PubMed ID: 30459772
[TBL] [Abstract][Full Text] [Related]
35. Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma.
Lee HT; Kim Y; Park UB; Jeong TJ; Lee SH; Heo YS
Biochem Biophys Res Commun; 2021 Jan; 536():26-31. PubMed ID: 33360095
[TBL] [Abstract][Full Text] [Related]
36. Immunomodulatory effects of CD38-targeting antibodies.
van de Donk NWCJ
Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
[TBL] [Abstract][Full Text] [Related]
37. Comparison of CD38-Targeted α- Versus β-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model.
Minnix M; Adhikarla V; Caserta E; Poku E; Rockne R; Shively JE; Pichiorri F
J Nucl Med; 2021 Jun; 62(6):795-801. PubMed ID: 33127621
[TBL] [Abstract][Full Text] [Related]
38. A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.
Green DJ; Orgun NN; Jones JC; Hylarides MD; Pagel JM; Hamlin DK; Wilbur DS; Lin Y; Fisher DR; Kenoyer AL; Frayo SL; Gopal AK; Orozco JJ; Gooley TA; Wood BL; Bensinger WI; Press OW
Cancer Res; 2014 Feb; 74(4):1179-89. PubMed ID: 24371230
[TBL] [Abstract][Full Text] [Related]
39. Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature.
Barbieri E; Martino EA; Rivolti E; Quaresima M; Vigna E; Neri A; Morabito F; Gentile M
Expert Opin Biol Ther; 2024 May; 24(5):365-381. PubMed ID: 38757726
[TBL] [Abstract][Full Text] [Related]
40. Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.
Kriegsmann K; Dittrich T; Neuber B; Awwad MHS; Hegenbart U; Goldschmidt H; Hillengass J; Hose D; Seckinger A; Müller-Tidow C; Ho AD; Schönland S; Hundemer M
Cytometry B Clin Cytom; 2018 Sep; 94(5):611-620. PubMed ID: 29577600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]